https://www.selleckchem.com/products/17-AAG(Geldanamycin).html Immune checkpoint inhibitors (ICIs) have shown significant efficacy in various solid tumors, but only a small subgroup of patients benefit from them because of immune resistance. Oncorine (formerly H101), a recombinant human adenovirus type 5, has direct anticancer properties and enhances cell-mediated immune responses. At present, few studies on the role of Oncorine in reversing resistance to ICIs have been reported. Here, we present a case with recurrent non-small cell lung cancer (NSCLC). The patient developed resistance to nivolumab therapy. After trying immunotherapy plus chemotherapy or antiangiogenesis therapy, the patient only obtained a transient response. The patient then received experimental treatment with Oncorine together with nivolumab and anlotinib. She experienced symptomatic improvement with a performance status score of 1, and achieved stable disease despite partial lung tissue necrosis. This was a successful exploration of oncolytic viruses reversing immune resistance.Molybdenum oxycarbide clusters are novel nanomaterials that exhibit attractive catalytic activity; however, the methods for their production are currently very restrictive. This work represents a new strategy for the creation of near-subnanometer size molybdenum oxycarbide clusters on multilayer graphene. To adsorb Mo-based polyoxometalates of the type [PMo12 O40 ]3- as a precursor for Mo oxycarbide clusters, the novel tripodal-phenyl cation N,N,N-tri(4-phenylbutyl)-N-methylammonium ([TPBMA]+ ) is synthesized. [TPBMA]+ exhibits superior adsorption on multilayer graphene compared to commercially available cations such as tetrabutylammonium ([nBu4 N]+ ) and tetraphenylphosphonium ([PPh4 ]+ ). Using [TPBMA]+ as an anchor, highly dispersed precursor clusters (diameter 1.0 ± 0.2 nm) supported on multilayer graphene are obtained, as confirmed by high-resolution scanning transmission electron microscopy. Remarkably, this new ma